Lynne Neumayr

4.8k total citations · 1 hit paper
56 papers, 2.8k citations indexed

About

Lynne Neumayr is a scholar working on Genetics, Hematology and Orthopedics and Sports Medicine. According to data from OpenAlex, Lynne Neumayr has authored 56 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Genetics, 31 papers in Hematology and 11 papers in Orthopedics and Sports Medicine. Recurrent topics in Lynne Neumayr's work include Hemoglobinopathies and Related Disorders (43 papers), Iron Metabolism and Disorders (19 papers) and Blood groups and transfusion (18 papers). Lynne Neumayr is often cited by papers focused on Hemoglobinopathies and Related Disorders (43 papers), Iron Metabolism and Disorders (19 papers) and Blood groups and transfusion (18 papers). Lynne Neumayr collaborates with scholars based in United States, United Kingdom and Canada. Lynne Neumayr's co-authors include Elliott Vichinsky, Ann N. Earles, Miguel R. Abboud, Charles M. Haberkern, Mabel Koshy, Dennis M. Black, Eugene P. Orringer, Rita Bellevue, Evelyne T. Lennette and Russell E. Ware and has published in prestigious journals such as New England Journal of Medicine, Blood and Neurology.

In The Last Decade

Lynne Neumayr

54 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease

2000 800 citations Elliott Vichinsky, Lynne Neumayr et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Lynne Neumayr

Since Specialization

Citations

This map shows the geographic impact of Lynne Neumayr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynne Neumayr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynne Neumayr more than expected).

Fields of papers citing papers by Lynne Neumayr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynne Neumayr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynne Neumayr. The network helps show where Lynne Neumayr may publish in the future.

Co-authorship network of co-authors of Lynne Neumayr

This figure shows the co-authorship network connecting the top 25 collaborators of Lynne Neumayr. A scholar is included among the top collaborators of Lynne Neumayr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynne Neumayr. Lynne Neumayr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL 2025 ·Blood ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, (unknown), Cathy Zhou, (unknown), Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	5
2	CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, Anita Szőke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	4
3	Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, (unknown), Lynne Neumayr, James Dean, Paolo Ghia, Thomas J. Kipps	5
4	Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up 2024 ·Blood ·Jan A. Burger, Neil E. Kay, John N. Allan, Paul M. Barr, Jacqueline C. Barrientos, Carolyn Owen, Victoria Wang, Hsin-Hui Huang, Lynne Neumayr, (unknown), (unknown), Shefali Mody, Paolo Ghia, Tait D. Shanafelt	0
5	P645: IBRUTINIB FOR TREATMENT OF RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHING-ADJUSTED INDIRECT COMPARISON OF 3 RANDOMIZED PHASE 3 TRIALS 2023 ·HemaSphere ·Paolo Ghia, Talha Munir, Jan A. Burger, John F. Seymour, Kerry A. Rogers, Hsin-Hui Huang, Carol Moreno, Lynne Neumayr, (unknown), Jeff P. Sharman	1
6	PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 2022 ·HemaSphere ·Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Constantine S. Tam, Paolo Ghia, Carol Moreno, Neil E. Kay, Tanya Siddiqi, Edith Szafer‐Glusman, Cathy Zhou, Lynne Neumayr, (unknown), William G. Wierda, Tait D. Shanafelt	1
7	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) 2018 ·Blood Advances ·Ahmed Daak, Carlton Dampier, Beng Fuh, Julie Kanter, Ofelia Álvarez, (unknown), (unknown), Michael U. Callaghan, Alex George, Lynne Neumayr, Lee Hilliard, (unknown), Adrián L. Rabinowicz, Matthew M. Heeney	31
8	Neuroimaging abnormalities in adults with sickle cell anemia 2014 ·Neurology ·R. Scott Mackin, Philip S. Insel, Diana Truran, Elliott Vichinsky, Lynne Neumayr, F. Daniel Armstrong, Jeffrey I. Gold, Karen Kesler, Joseph M. Brewer, Michael W. Weiner	54
9	Mechanisms of plasma non‐transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients 2014 ·British Journal of Haematology ·John B. Porter, Patrick B. Walter, Lynne Neumayr, Patricia Evans, Sukhvinder S. Bansal, Maciej Garbowski, (unknown), Paul Harmatz, John C. Wood, Jeffery L. Miller, Colleen Byrnes, Günter Weiß, Markus Seifert, Regine Grosse, (unknown), A Schmidt, Roland A. Fischer, Peter Nielsen, Charlotte M. Niemeyer, Elliott Vichinsky	52
10	A phase 1/2 trial of HQK‐1001, an oral fetal globin inducer, in sickle cell disease 2012 ·American Journal of Hematology ·Abdullah Kutlar, Kenneth I. Ataga, Marvin Reid, Elliott Vichinsky, Lynne Neumayr, (unknown), Richard Labotka, Jonathan Glass, Jeffrey R. Keefer, William A. Wargin, Ronald Berenson, Susan P. Perrine	24
11	Combined chelation therapy with deferasirox and deferoxamine in thalassemia 2012 ·Blood Cells Molecules and Diseases ·Ashutosh Lal, John B. Porter, Nancy Sweeters, Vivian Ng, Patricia Evans, Lynne Neumayr, Gregory Kurio, Paul Harmatz, Elliott Vichinsky	73
12	The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial 2011 ·British Journal of Haematology ·Winfred C. Wang, Carlo Brugnara, (unknown), Lynn Wynn, Zora R. Rogers, Karen Kalinyak, R. Clark Brown, Muhammad Asif Qureshi, Carolyn Bigelow, Lynne Neumayr, Kim Smith‐Whitley, David H.K. Chui, (unknown), (unknown), Martin H. Steinberg, Marilyn J. Telen, Karen Kesler	30
13	Red blood cell transfusion in pediatric patients with severe chronic anemia: How slow is necessary? 2011 ·Pediatric Blood & Cancer ·Anurag K. Agrawal, (unknown), Keith Quirolo, Lynne Neumayr, Heidi R. Flori	11
14	Clinical Evaluation of Avascular Necrosis in Patients With Sickle Cell Disease: Children’s Hospital Oakland Hip Evaluation Scale—A Modification of the Harris Hip Score 2005 ·Archives of Physical Medicine and Rehabilitation ·Christine Aguilar, Lynne Neumayr, (unknown), (unknown), Shanda Robertson, Harry E. Jergesen, Bernard N. Stulberg, Elliott Vichinsky	38
15	Bone and Joint Disease in Sickle Cell Disease 2005 ·Hematology/Oncology Clinics of North America ·Christine Aguilar, Elliott Vichinsky, Lynne Neumayr	44
16	Chlamydia pneumoniae and Acute Chest Syndrome in Patients With Sickle Cell Disease 2003 ·Journal of Pediatric Hematology/Oncology ·Deborah Dean, Lynne Neumayr, (unknown), Samir K. Ballas, Klara Kleman, Shanda Robertson, Rathi V. Iyer, Russell E. Ware, Mabel Koshy, Wayne Rackoff, (unknown), Peter Waldron, Lennette J. Benjamin, Elliott Vichinsky	38
17	Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease breakdown → 2000 ·New England Journal of Medicine ·Elliott Vichinsky, Lynne Neumayr, Ann N. Earles, Roger Williams, Evelyne T. Lennette, Deborah Dean, Bruce G. Nickerson, Eugene P. Orringer, Virgil McKie, Rita Bellevue, Charles Daeschner, Miguel R. Abboud, Mark D. Moncino, Samir K. Ballas, Russell E. Ware, Elizabeth A. Manci	800
18	The perioperative complication rate of orthopedic surgery in sickle cell disease: Report of the national sickle cell surgery study group 1999 ·American Journal of Hematology ·Elliott Vichinsky, Lynne Neumayr, Charles M. Haberkern, Ann N. Earles, (unknown), Mabel Koshy, Dennis M. Black	114
19	Tonsillectomy, Adenoidectomy, and Myringotomy in Sickle Cell Disease 1999 ·Journal of Pediatric Hematology/Oncology ·Peter Waldron, Charles H. Pegelow, Lynne Neumayr, Charles M. Haberkern, Ann N. Earles, (unknown), Elliott Vichinsky	35
20	A Comparison of Conservative and Aggressive Transfusion Regimens in the Perioperative Management of Sickle Cell Disease 1995 ·New England Journal of Medicine ·Elliott Vichinsky, Charles M. Haberkern, Lynne Neumayr, Ann N. Earles, Dennis M. Black, Mabel Koshy, Charles H. Pegelow, Miguel R. Abboud, Kwaku Ohene‐Frempong, Rathi V. Iyer	430

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact